The consensus molecular subtypes of colorectal cancer

Colorectal cancer (CRC) is a frequently lethal disease with heterogeneous outcomes and drug responses. To resolve inconsistencies among the reported gene expression-based CRC classifications and facilitate clinical translation, we formed an international consortium dedicated to large-scale data shar...

Descripción completa

Detalles Bibliográficos
Autores: Guinney, Justin, Dienstmann, Rodrigo, Wang, Xin, Reyniès, Aurélien de, Schlicker, Andreas, Soneson, Charlotte, Marisa, Laetitia, Roepman, Paul, Nyamundanda, Gift, Angelino, Paolo, Bot, Brian M., Morris, Jeffrey, Simon, Iris M., Gerster, Sarah, Fessler, Evelyn, Sousa e Melo, Felipe de, Missiaglia, Edoardo, Ramay, Hena, Barras, David, Homicsko, Krisztian, Maru, Dipen, Manyam, Ganiraju C., Broom, Bradley, Boige, Valerie, Pérez Villamil, Beatriz, Laderas, Ted, Salazar Soler, Ramón, Gray, Joe W., Hanahan, Douglas, Tabernero Caturla, Josep, Bernards, René, Friend, Stephen H., Laurent Puig, Pierre, Medema, Jan Paul, Sadanandam, Anguraj, Wessels, Lodewyk F. A., Delorenzi, Mauro, Kopetz, Scott, Vermeulen, Louis, Tejpar, Sabine
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2015
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/127368
Acceso en línea:https://hdl.handle.net/2445/127368
Access Level:acceso abierto
Palabra clave:Càncer colorectal
Classificació de tumors
Oncologia
Colorectal cancer
Tumors classification
Oncology
Descripción
Sumario:Colorectal cancer (CRC) is a frequently lethal disease with heterogeneous outcomes and drug responses. To resolve inconsistencies among the reported gene expression-based CRC classifications and facilitate clinical translation, we formed an international consortium dedicated to large-scale data sharing and analytics across expert groups. We show marked interconnectivity between six independent classification systems coalescing into four consensus molecular subtypes (CMSs) with distinguishing features: CMS1 (microsatellite instability immune, 14%), hypermutated, microsatellite unstable and strong immune activation; CMS2 (canonical, 37%), epithelial, marked WNT and MYC signaling activation; CMS3 (metabolic, 13%), epithelial and evident metabolic dysregulation; and CMS4 (mesenchymal, 23%), prominent transforming growth factor-beta activation, stromal invasion and angiogenesis. Samples with mixed features (13%) possibly represent a transition phenotype or intratumoral heterogeneity. We consider the CMS groups the most robust classification system currently available for CRC-with clear biological interpretability-and the basis for future clinical stratification and subtype-based targeted interventions.

Similares en LA Referencia